Jurgen K. Rockstroh

Jurgen K. Rockstroh

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 392 publications

Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.

Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.

Journal: The New England journal of medicine
Published: July 29, 2026

Paucisymptomatic opisthorchiasis in a non-endemic country: a neglected differential diagnosis?

Paucisymptomatic opisthorchiasis in a non-endemic country: a neglected differential diagnosis?

Journal: Infection
Published: March 31, 2026

Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates.

Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates.

Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: February 13, 2026

The double burden: navigating HIV co-infections with HCV, HBV, and Mtb.

The double burden: navigating HIV co-infections with HCV, HBV, and Mtb.

Journal: Current opinion in HIV and AIDS
Published: February 05, 2026

FIB-4 fails to identify significant liver fibrosis in people with HIV: A large multinational screening study.

FIB-4 fails to identify significant liver fibrosis in people with HIV: A large multinational screening study.

Journal: Hepatology (Baltimore, Md.)
Published: February 04, 2026

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: January 14, 2026

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Journal: The lancet. HIV
Published: January 12, 2026

Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy.

Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy.

Journal: The Journal of antimicrobial chemotherapy
Published: January 06, 2026

An overview of consent requirements for HIV and viral hepatitis B and C testing in Europe.

An overview of consent requirements for HIV and viral hepatitis B and C testing in Europe.

Journal: HIV medicine
Published: January 06, 2026

Characterization of post-COVID syndrome by self-perceived symptom severity stratified by infection wave: beyond COVID, a prospective, multicenter cohort study in Germany.

Characterization of post-COVID syndrome by self-perceived symptom severity stratified by infection wave: beyond COVID, a prospective, multicenter cohort study in Germany.

Journal: Infection
Published: December 31, 2025

Long-term immune recovery under continuous antiretroviral therapy (ART) among ART-naive people living with HIV in two cohorts in Germany.

Long-term immune recovery under continuous antiretroviral therapy (ART) among ART-naive people living with HIV in two cohorts in Germany.

Journal: Infection
Published: December 18, 2025

Considerations for the Use of AAV-based Gene Therapy in HIV-Positive Individuals With Haemophilia.

Considerations for the Use of AAV-based Gene Therapy in HIV-Positive Individuals With Haemophilia.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: November 06, 2025
Showing 1-12 of 392

Last Updated: 09/26/2026